# Sanofi: Phase 2 study terminated, 105 enrolled (Crohn's Disease)

**Score:** 70/100

| Field | Value |
|---|---|
| Sponsor | Sanofi |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. |
| NCT ID | NCT06637631 |
| Phase | Phase 2 |
| Status | terminated |
| Conditions | Crohn's Disease |
| Intervention types | drug |
| Target enrollment | 105 |
| Site countries | United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czechia, France, Georgia |
| Posted | 2024-10-15 |
| Planned start | 2024-12-10 |
| Event | Terminated |
| Event date | 2026-10-02 |
| Last update posted | 2026-10-13 |

## Why this score
- Industry sponsor (buys outsourced services).
- Stopped early: budget and sites freed up.
- Phase 2: multi-site, larger budget.
- 105 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06637631). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.